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Guts & Glory H. pylori: Cause of Peptic Ulcer
 
Ashley Johnson*, Bryan Kratz*, Lorraine 
Scanlon*, and Alina Spivak* 
Department of Biology 
Lake Forest College 
Lake Forest, Illinois 60045 
 
Summary  
 
Due to the 1983 discovery of H. pylori bacteria as 
the leading cause of peptic ulcers, the 
understanding of the disease dramatically changed. 
We now know that stress and spicy foods are not 
the leading causes of peptic ulcers. Symptoms 
including acute abdominal pain, vomiting of blood, 
and weight loss are characteristic of peptic ulcers. 
Ulcers form because of the inflammation caused by 
H. pylori leading to sensitivity of gastric cells to the 
acid secreted by the infected patient’s stomach. 
Although more than half of the world’s population 
is infected with H. pylori, most people remain 
asymptomatic. Current research suggests that 
several bacterial virulence genes such as CagA and 
VacA, as well as the individual host’s genetic 
predisposition, are factors that influence 
progression of disease. The mechanism of H. pylori 
infection has been recently examined in detail 
clarifying the morphological changes of the host 
cell and how this promotes the formation of a 
peptic ulcer. Present studies  to explain the 
persistence of H. pylori and propose how this 
bacterium evolved key mechanisms to evade the 
host’s immune response. Due to the advances in 
the understanding of peptic ulcers, effective 
treatments have been proposed to treat and 
eliminate this disease. 
 
History 
 
In 1983, Australian scientists Robin Warren and Barry 
Marshall showed that the leading cause of peptic ulcers 
is the infection of the stomach lining with a helical 
(spiral) shaped gram negative bacterium Helicobacter 
pylori (H. pylori). It was previously believed that peptic 
ulcers were caused by stress and consumption of spicy 
foods (1). 
 
Characteristics 
 
H. pylori infection leads to inflammation of the gastric 
mucosa in 80% of peptic ulcer cases. H. pylori cause 
elevated acid secretion in people who develop 
duodenal ulcers, and decreased acid secretion in those 
who develop gastric ulcers and gastric cancer (3, 5). 
Duodenal ulcers form due to acid hypersecretion in 
response to antral inflammation. In patients with gastric 
ulcers, H. pylori cause corpus inflammation which leads 
to decreased acid secretion and gastric atrophy (Figure 
1). Peptic ulcers are 0.3-0.4 cm in diameter in the 
affected area of the stomach. The remaining 20% of 
peptic ulcer cases are caused by nonsteroidal anti-
inflammatory drugs (NSAIDS) like aspirin, which irritate 
the stomach lining (3). NSAIDS hinder the protective 
mechanisms of the stomach including mucus and  
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Bicarbonate  secretions,  and  reduce  blood  circulation 
which  aids  in  cell  renewal  and repair. With the host’s 
defenses down, stomach acid can irritate the sensitive 
lining, thus causing ulcers (5, 6). 
 
Gut Wrenching Diseases 
 
Peptic Ulcers 
Peptic ulcers form on the epithelial cells of the stomach 
lining. An ulcer consists of two major structures: a 
distinct ulcer margin and granulation tissue at the ulcer 
base.   A distinct ulcer margin is formed by the adjacent 
non-necrotic mucosa - the epithelial component.  The 
granulation tissue consists of fibroblasts, macrophages, 
and proliferating endothelial cells,  which form 
microvessels. On the molecular level, the pathogenesis 
of ulcer disease is believed to reflect an imbalance 
between increased corrosive stomach byproducts and 
decreased protective factors. As a result of stimulation 
arising from the sight, smell, taste, or thought of food, 
acetylcholine, a neurotransmitter, and gastrin, a 
hormone, are released and act on the parietal cells to 
produce acid.  The mast cells in turn release histamine, 
which also stimulates gastric acid secretion. In patients 
infected with H. pylori, the parietal cells have increased 
sensitivity to gastrin and possibly to histamine. The 
increased sensitivity causes corrosion of the stomach 
lining, leading to the formation of an ulcer (2). 
 
Gastric Cancer 
H. pylori trigger the host's immune system to release 
immune response mediators. These molecules, such as 
reactive oxygen species and nitrogen made by 
neutrophils, are released in the stomach and undergo 
lysis due to low pH levels. These molecules can often 
damage DNA. Patients with gastric cancer often have 
constantly activated oncogenes, such as c-met, c-erbB-
2, K-sam, or inactivated tumor-suppressor genes, such 
as p53, p16, and APC. Those affected also show 
abnormal alterations of genes implicated in cell 
proliferation and apoptosis, such as cyclin D1, bcl-2, 
E2F-1, and SC-1(7). 
 
Not-So-Glorious Symptoms 
 
One of the major symptoms of gastric ulcers is 
abdominal pain, which usually occurs during mealtimes 
as more acid is secreted into the stomach. 
Hematemesis (vomiting of blood) is often seen in 
patients with gastric ulcers, which leads to a noticeable 
reduction in the patient’s weight. Melena (i.e. foul 
smelling feces) is another symptom of gastric ulcers 
that is often caused by the presence of oxidized iron 
from hemoglobin (2).  
 
Environmental Pitfalls 
A diet high in salt and lacking antioxidant vitamins might 
promote low acid secretion and cause gastritis, which 
leads to gastric ulcers and gastric cancer. Salt may 
change acid secretion by suppressing parietal cells, 
causing gastric atrophy. Also, the antioxidant vitamins 
in fresh fruit might protect specialized gastric cells from 
reactive oxygen species released by inflammatory cells. 
Diet confirms why there is a high prevalence of ulcers in 
China and Japan. These countries not only have a high 
prevalence of H. pylori but also a traditionally salty diet.
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Figure 1. H. pylori induced changes in stomach functioning lead to several gastrointestinal diseases Infection with H. pylori leads to 
hypergastrinemia which may lead to inflammation depending on bacterial virulence, environmental factors, and host genetic differences.  
Patients who develop inflammation of the gastric corpus exhibit decreased acid production which may lead to gastric cancer or gastric 
ulcer. Those who maintain a healthy gastric corpus but have gastric antral inflammation exhibit increased acid production, which may lead 
to duodenal ulcers.
 
Cigarette smoking also strongly predisposes to both 
duodenal ulcer and gastric cancer (3). 
 
You’ve “Gut” to Take These 
 
The most effective treatment for peptic ulcers is a three 
drug regimen consisting of a proton pump inhibitor 
(PPI) and two antibiotics. Proton pump inhibitors work 
to expose H. pylori to the drug treatment. The most 
common antibiotic used is amoxicillin and the most 
prevalent PPI is Omeprazole. Once the bacteria are 
eradicated by the drug regimen, the normal immune 
response has the full potential to regenerate the 
stomach lining and heal the ulcer. 
What’s Left to Stomach 
Although a lot is already known about H. 
pylori and the diseases it causes, there are four major 
areas that are currently being expanded on. The fact 
that the bacterium resides in so many people yet 
symptoms of disease only appear in a few people is 
intriguing. This question led researchers to investigate 
whether bacterial virulence factors and differences in 
the host attribute to this discrepancy. In addition, the 
persistence of the bacterium in the infected individual 
suggests the possibility, addressed by current research, 
that H. pylori evolved key mechanisms to evade the 
host's immune responses. Studies of the molecular 
mechanism of the invasion of the gastric cells with H. 
pylori have been elaborated upon in recent years. Also, 
new therapeutic agents and methods of treatment of 
gastrointestinal diseases have been proposed in 
response to new findings.  
 
Disease or No Disease…That is the question 
 
Current research suggests that several bacterial 
virulence factors such as CagA and VacA genes, as 
well as the individual host’s genetic predisposition, 
influence progression of H. pylori-related diseases.  The 
World Health Organization recently has classified H. 
pylori as a class I carcinogen because of the risk factor  
 
of developing gastric carcinoma as a result of chronic 
infection (4, 5, 6).  
  
VacA: Evacuate my body 
 
The H. pylori vacuolating cytotoxin gene, vacA, is 
naturally polymorphic. The two most diverse regions 
being are the signal region (which can be type s1 or s2) 
and the mid region (m1 or m2).  The type s1/m1 and 
s1/m2 strains of vacA are associated with peptic ulcer 
and gastric cancer, whereas while the type s2/m2 
strains are non-toxic and associated with lower risk of 
peptic ulcer and gastric cancer. The features of vacA 
that determine the nontoxicity of these strains were 
determined by Letley et. al. (2003).  They did this by 
deleting parts of vacA and constructing isogenic hybrid 
strains in which regions of vacA were exchanged 
between toxigenic and non-toxigenic strains.  They 
showed that a naturally-occurring 12-amino acid 
hydrophilic N-terminal extension found on  
s2 VacA blocks vacuolating activity as while its removal 
(making the strain s1-like) confers activity. They did 
chromosomal replacement of vaca in a nontoxigenic 
strain with vacA from a toxigenic strain and found full 
activating activity, proving that the vacoulation is 
controlled entirely by elements within vacA.  This 
research defined why determined that H. pylori strains 
with different vacA allelic structures have differing 
toxicity (10).   
 
Virulent Strain Carries CagA Gene  
 
Another bacterial virulence factor is the polymorphism 
of the CagA protein.  All H. pylori strains have the 
cagPAI DNA segment, but only some strains have the 
cagA gene that encodes the 145 -kDA CagA protein. 
These strains are called cagA+ strains, and while the 
strains lacking the cagA gene are called cagA-.  The 
cagA+ strains are more virulent than the cagA- strains 
and are associated with gastric carcinoma.  The CagA 
is injected by the bacterium and subsequently 
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undergoes tyrosine phosphorylation.  The 
phosphorylated CagA specifically binds SHP-2 
phophatase, activates the phophatase activity, and 
thereby induces morphological transformation of cells.  
SHP-2 plays an important role in both cell growth and 
cell motility.  This morphological change is referred to 
as the hummingbird phenotype because the cell 
undergoes dramatic elongation by means of the 
attachment of cagA+.  Higashi et. al. (2002) found that 
Western and East Asian CagA both contain tyrosine 
phosphorylation sites but they differ in structure.  
Western strains can have repeating tyrosine 
phosphorylation sites.  The larger the number of binding 
sites, the greater the amount of tyrosine 
phosphorylation, which leads to increased SHP-2 
binding and greater morphological changes.  In 
contrast, the East Asian strains have a different tyrosine 
phosphorylation sequence at the region corresponding 
to the Western sequence that binds SHP-2 stronger 
and induces greater morphological changes to the cell 
than the Western sequence, causing East Asian CagA 
proteins to be more potent and leading to high gastric 
cancer incidence rates (9).  
 
Interleukin-1 β  What alleles do you have? 
 
Host genetic factors that affect interleukin-1-beta may 
determine why some individuals affected with H. pylori 
develop gastric cancer while others do not. 
Polymorphisms in human cytokine genes affect the 
level of cytokine production by cells after contact with 
H. pylori.  Specific polymorphisms in the IL-1b gene and 
the IL-1 receptor-antagonist gene (IR-1RN) lead to 
increased gastric mucosal levels of IL-1b in individuals 
infected with H. pylori.  IL-1b (interleukin-1-beta) is an 
important pro-inflammatory cytokine and a powerful 
inhibitor of gastric acid secretion (5).  The three 
reported diallelic polymorphisms in IL1B which have 
been reported all represent C-to-T base transitions at 
positions –511, -31, and +3954 basepairs from the 
transcriptional start site.   El-Omar et al., demonstrated 
that individuals who were carriers for of the interleukin-1 
beta- 31T allele had low acid secretion. The 
polymorphisms also increase the risk of gastric atrophy, 
hypochlorhydria, intestinal metaplasia, and gastric 
cancer (5, 8).  Using electrophoretic mobility shift 
analysis to assess DNA binding in vitro, the interleukin-
1 beta -31T allele was associated with a five-fold 
increase in DNA-binding after lipopolsaccharide 
stimulation. Individuals carrying the interleukin-1 beta -
31 T allele are more susceptible to developing 
hypochlorhydria, and subsequently gastric cancer, in 
the case of an infection by the bacterium H. pylori. 
Thus, the interleukin-1 beta gene is a crucial factor in 
determining if a person will develop gastric cancer (8).    
 
Gastric Cancer  
 
Infection with the human microbial pathogen 
Helicobacter pylori is assumed to lead to invasive 
gastric cancer. H. pylori activate the hepatocyte growth 
factor/scatter factor receptor c-Met (oncogene), which is 
involved in invasive growth of tumor cells. The H. pylori 
effector protein CagA intracellularly targets the c-Met 
receptor and acts as an oncoprotein, promoting cellular 
processes that lead to changes in cell polarity, motility 
and differentiation. These changes may be related to 
the development of gastric cancer. CagA could 
represent a bacterial adaptor protein that associates 
with phospholipase Cγ (PCγ), but not with Grb2-
associated binder 1 or growth factor receptor–bound 
protein 2. The H. pylori–induced motogenic response is 
suppressed and blocked by the inhibition of PLCγ and 
of MAPK, respectively. Thus, upon translocation, CagA 
modulates cellular functions by deregulating c-Met 
receptor signaling. The activation of the motogenic 
response in H. pylori–infected epithelial cells suggests 
that CagA could be involved in tumor progression (8).  
 
H. pylori Persistence 
The primary response of the body to infection of H. 
pylori is inflammation. This is caused by the infiltration 
of the gastric mucosa with neutrophils, macrophages, B 
cells, and T cells following release of interleukins. T 
lymphocyte responses in acute H. pylori infection are 
predominantly of the CD4+ Th1 (mainly cell-mediated) 
cell phenotype (3, 5).  Although a seemingly large 
immune response is initiated, it is mostly ineffective, 
because H. pylori bacteria are rarely completely 
eradicated from an infected individual. The persistence 
of H. pylori and the high reinfection rate suggest that 
the host has significant anergy and is unable to build 
protective immunity.  
 
VacA Does What? 
 
Previous studies showed that VacA inhibits release of 
IL-2 in Jurkat cells (human T-cell leukemia cells). This 
inhibition is linked to the ability of VacA to inactivate the 
Nuclear Factor of Activated T-cells (NFAT). This 
transcription factor is critical to the transcription of IL-2; 
therefore, if VacA inactivates NFAT, IL-2 secretion is 
inhibited, and Jurkat T cell proliferation is therefore 
decreased (11).  
However, Sundrud et al. (2004) propose that 
VacA has a different effect on primary human Th cells. 
Similar testing with the human Th cells suggested that 
VacA has only a modest effect on IL-2 secretion. VacA 
did not cause a reduction in IL-2 levels in either naïve 
or memory Th cells. Therefore, it is now predicted that 
VacA inhibits IL-2-driven proliferation of primary human 
Th cells by a non-NFAT mechanism. Further studies 
suggested that VacA suppresses cell cycle progression 
in Th cells, similar to drugs such as rapamycin which 
induce G1 arrest. Therefore, instead of blocking IL-2 
secretion, and by that inhibiting Th cell proliferation in 
human Th cells, VacA might be blocking normal cell 
cycle progression of these cells. Sundrud et al. found 
that VacA must have an intact hydrophobic domain 
within its N-terminal region. This component of VacA 
structure is necessary for both inhibition of IL-2 
secretion in Jurkat cells and inhibition of IL-2-driven 
proliferation of human primary Th cells. This region is 
attributed to making VacA anion-selective channels, 
which may cause depolarization of the Th cell plasma 
membrane and lead to inhibition of IL-2- dependent T-
cell proliferation.  Interestingly,  a mutant VacA (VacA- 
(6-27) that completely lacks this entire hydrophobic 
region actually has a dominant negative effect and fully 
blocks the wildtype VacA mediated inhibition of T cell 
proliferation both in Jurkat and primary human Th cells. 
Thus, these scientists concluded that VacA has 
immunosuppressive properties that help H.pylori evade 
the host’s immune response (11). 
 
Treg Cells don’t regulate but promote disease 
 
Recent studies show that the host’s immune response 
often leads to immunopathology in an infected person 
(3, 5, 7). This conclusion stems from the fact that Th 
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cells have a poor responsiveness to H. pylori antigens. 
CD4+ T cells proliferate more during H. pylori infection 
in comparison to CD8+ T cells. Also, Lundgren et al. 
(2003) suggest that memory cells in infected individuals 
proliferate a lot less in comparison to the memory cells 
of healthy individuals, and naïve cells barely proliferate 
in either case. In fact, this difference in proliferation 
rates of memory cells was nonexistent when both 
individuals were treated with another toxin (Tetanus-
toxin). This implies that the reduced responsiveness of 
memory T cell proliferation in infected individuals was 
limited to H. pylori specific cells. This finding led to the 
assumption that regulatory CD4+CD25high T cells (Treg 
cells) suppress proliferation of memory T-cells. Treg 
cells are vital for controlling the immune response to 
foreign antigens and preventing autoimmune 
responses. Therefore, it is currently suggested that 
repetitive stimulation of T cells with H. pylori antigen 
may lead to activation of Treg cells that actively 
suppress the response of memory cells. Therefore, 
these authors showed that with prolonged infection, the 
host’s own immunity activates H. pylori specific Treg 
cells, which suppress memory cell proliferation 
promoting pathogenesis (12). 
 
(COX) 4 Lowers Immune Response 
 
Meyer et al. (2003) found that H. pylori induce 
production of cyclooxygenase (COX) 4-2. COX is an 
enzyme that is attributed to inhibition of epithelial 
apoptosis, increased cell proliferation, and 
angiogenesis. Studies have shown that a byproduct of 
H. pylori, urease, allows the bacteria to survive the 
acidic pH of the stomach and also induces (COX) 4-2 
expression (5, 13). (COX) 4-2 then produces 
prostaglandins such as prostaglandin E2 (PGE2) which 
mediate inflammation. Therefore, the induction of 
(COX) 4-2 by the host is a defense strategy that works 
by making PGE2 that reduces inflammation. Also, 
Meyer et al. (2003) found that a decrease of 
inflammation has been attributed to increased bacterial 
colonization. Therefore, H. pylori inhibit the 
effectiveness of the host’s immune response leading to 
increased pathology (13). 
 
Le+ H. pylori have an advantage 
 
Horizontal gene transfer and translational frame shifts 
contribute to the large genetic diversity of this bacterium 
(5). Bergman et al (2005) showed  that H. pylori 
express Lewis blood group Antigen (Le) in their 
lipopolysaccharide (LPS) that is phase variable, 
resulting in Le+ and Le- population of H. pylori within a 
single strain. Similar to HIV, Le+ antigen of H. pylori 
variants can bind to the C-type lectin DC-SIGN and 
present on gastric dendritic cells (DCs). This interaction 
induces inhibition of Th1 cell differentiation as 
compared to nonbinding variants. Le+ antigen alter the 
host’s T cell ability to differentiate by reducing the 
amount of IL-6 produced and blocks Th 1 cell 
polarization. Similar to the Treg suppression of the 
immune response, the binding of Le+ antigen to DC-
SIGN reduces IL-6 levels which may lead to increased 
T cell sensitivity to suppression. Therefore, H. pylori 
targets DC-SIGN to block a polarized Th1 cell response 
by phase-variable expression of Le antigens. Once 
again, decreased proliferation of Th1 cells lead to a 
decrease in the host’s immune response (14). 
 
 
H. pylori Learned to Avoid TLR 
 
It is widely known that eukaryotic organisms have 
evolved many mechanisms to recognize bacterial 
agents so that a proper immune response can be 
activated to eradicate the bacterium. One such 
immunity are Toll-like receptors (TLRs), which 
recognize components of bacterial membrane LPS and 
a bacterial protein flagellin that are released by many 
gram-negative bacteria. Gewirtz et al. (2004) suggested 
that although H. pylori contain both LPS and flagella, 
they are still able to evade this immune response. The 
scientists found that H. pylori releases much smaller 
amounts of flagellin than other gram-negative bacteria 
and the flagellin that they do release is barely potent. 
The flagellin that is released does not play a large role 
in mediating proinflammatory gene expression in the 
host. The usual effect of gram-negative bacteria is the 
activation of TLR, which induces IL-8 secretion of a 
proinflammatory cytokine. However, H. pylori are able 
to evade TLR mediated immunity by producing 
impotent flagellin and preventing the release of this 
potentially immunogenic, proinflammatory protein (15). 
 
CagA vs.  Mucus 
 
CagA plays a major role in morphological changes 
induced by the Helicobacter pylori bacterium upon entry 
of the gastric epithelial cells. Al-Mahroon et al. (2004) 
preformed an experiment to test the effect of CagA (+) 
or CagA (-) strains of H. pylori on the mean gastric 
mucus thickness in humans when compared to an 
uninfected individual. Biopsies taken from each of the 
patients were submitted to PCR to determine the 
presence of CagA (+). After staining and treating the 
biopsies, the mucus layer thickness was determined 
using an integration of light microscopy, CCD camera, 
and specific computer software. The results showed 
that, on average, the mucus layer thickness was not 
affected in a manner that was statistically significant 
(20). 
 
I SAID Drop Your Apical Junctions Now! 
 
Another side effect of H. pylori infection is faulty apical 
junctions and loss of cell-to-cell adhesion. Scientists 
wondered if CagA plays a role in the mediation of this 
effect and how it causes this abnormal morphological 
change. Bagnoli (2005) preformed an experiment in 
which CagA and ZO-1(a known tight junction 
scaffolding protein) were tagged with antibodies so that 
they could be easily seen under the microscope. The 
results showed that in CagA expressing cells, the ZO-1 
protein was mislocated to the basolateral membrane 
(Figure 2). It was also found that the apical junction 
perimeter and the surface area of the apical membrane 
had become substantially reduced. As a result and 
consistent with their hypothesis, CagA expressing cells 
acquired an elongated, spindle-shaped morphology, 
and lost their connections with the apical junctions of 
neighboring cells (19). 
 
Hey SHP-2 Wanna Bind Tonight? 
 
A study conducted by Shiho Yamazaki et al. (2003) 
suggests that the CagA protein then may bind, undergo 
tyrosine phosphorylation, and form an activated-
complex with SRC homology 2 Domain (SHP-2). The 
phosphorylation of CagA and activation of SHP-2 are 
thought to induce the hummingbird phenotype: a
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Figure 2. Pathogen-Host Interactions in the Pathogenesis of H. pylori Infection 
Bacterial virulence factors CagA and VacA cause damage to the host cell. In response to bacterial colonization, a host mounts an immune 
response which often leads to disease. Several host proteins: ZO-1, SHP-2, c-Met, IL-1b, and Erk have been noted to be affected by CagA 
leading to formation of duodenal and gastric ulcers as well as gastric cancer. However, there are other effects of CagA that remain 
unknown and must be addressed in future research. Several treatments are used as a means to eradicate H. pylori infection such as 
antibiotics. Recent research proposes several alternative methods of treatment such as: mastic gum, genome-based drugs, and vaccines. 
Further research is still needed to clearly understand the pathology caused by H. pylori and optimal treatments.
 
morphological change characterized by elongation and 
contraction of the cell and increased cell motility. 
Normal SHP-2 is actively involved in regulation 
adhesion, spreading, and migration of cells. The 
scientists took biopsies at eight different parts of the 
stomach lining from fifteen patients who had either 
gastritis or early gastric cancer. The biopsies were 
submitted to immunoblotting and immunoprecipitation in 
conjunction with antibodies to detect CagA, 
phosphotyrosine, and SHP-2. The results detected the 
presence of tyrosine phosphorylated CagA protein and 
CagA-coimmunoprecipitated endogenous SHP-2. This 
suggests that deregulation of SHP-2 by translocated 
CagA can cause abnormal morphology and movement 
of gastric epithelial cells (16).  
 
Please Don’t Phosphorylate When Erk is Home 
 
Hideaki Higashi et. al (2004) investigated cellular 
proteins that bind to phosphorylated tyrosine but not 
non-phosphorylated CagA and form complexes SHP-2 
and subsequently with extracellular signal-regulated 
kinase (Erk), a MAP kinase signaling molecule that is 
thought to effect cell proliferation and motility.  To test 
the effect on the humming bird phenotype, they created 
a knock-out SHP-2 and transfected it into AGS cells. 
They found that only phosphorylated CagA complex 
with SHP-2 binds to and abnormally prolongs the 
activation of Erk (17). 
 
CagA Sticks like C-Met 
 
C-Met is a hepatocyte growth factor/scatter factor 
receptor that is involved in invasive growth of tumor  
 
cells. In a study conducted by Yuri Churin et al. (2003), 
the interaction of CagA with this receptor was tested.  
 
Small interference RNA was used to block the 
expression of c-met.  The blocking of c-Met expression 
inhibited scattering in AGS cells infected with CagA (+) 
H. pylori (18). 
 
What’s a Gut to do? 
 
Current treatment of Helicobacter pylori infection, which 
ultimately leads to the development of peptic ulcers, is 
based on multiple drug therapies (22). Currently, the 
most effective therapy consists of a proton-pump 
inhibitor and a series of three antibiotics chosen from 
macrolide antibiotics, ß-Lactam antibiotics, or 
metronidazole antibiotics (22). Other therapies, 
including two drugs (proton pump inhibitor and an 
antibiotic) and four drugs (proton pump inhibitor, three 
antibiotics), have also proven to eradicate H. pylori 
infection in humans (21).  
 
The Basic PPIs 
 
Proton pump inhibitors (PPIs) play an essential role in 
the eradication of H. pylori. PPIs act within the parietal 
cells of the stomach to inhibit H+, K+-ATPase activity. 
This enzyme maintains the balance of H+ and K+ ions 
within the cell so that pH is maintained inside and 
outside of the cell. PPIs bind to the H+, K+-ATPase on 
the outer luminal membrane and inhibit phosphorylation 
of ATP molecules. This in turn prevents the exchange 
of H+ and K+ ions. With the enzyme blocked, the acidic 
pH of the stomach is made more basic so that 
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antibiotics, which are taken along with PPIs, may reach 
the H. pylori living within the epithelial cells of the 
stomach (23).  
 
All PPIs are NOT Created Equal 
 
There are several PPIs that may be used in 
combination with antibiotics to eradicate H. pylori. The 
most common PPIs used are Omeprazole, 
Pantoprazole, Lansoprazole, and Rabeprazole. PPI 
differences depend on the H+, K+-ATPase binding 
location and their pharmacokinetic properties. 
 In comparison, Hellstrom and Sigurd (2004) found that 
Rabeprazole was very quick to inhibit acid production 
compared to the others; however, Omeprazole offered 
the most potent acid inhibition. Pantoprazole and 
Lansoprazole are not far behind Omeprazole and 
Rabeprazole in speed and potency, indicating that all 
four of these PPIs are effective ways to inhibit the 
function of the H+, K+-ATPase enzyme (23). 
 
Dealing the Drugs 
 
Current therapies used to eradicate H. pylori in the 
stomach all include at least one antibiotic in 
combination with a PPI. The main categories of 
antibiotics used are: macrolide antibiotics, ß-Lactam 
antibiotics, and Metronidazole antibiotics (21).  
 
Holy Macrolide 
 
Macrolide antibiotics accumulate in the epithelial 
tissues of the stomach. Here, they are able to inhibit 
RNA- dependent protein synthesis by binding to the 
23S ribosomal RNA in the 50S subunit of prokaryotic 
ribosomes.When the macrolides bind to the ribosomes, 
they inhibit peptidyl transferase reactions and cause 
incomplete peptide chains to be detatched from the 
ribosome. Proteins are essential for a cell to funciton, 
so without properly formed proteins, the bacteria die 
quickly (24). 
 
And The Walls Came Tumbling Down 
 
ß-Lactam antibiotics are analogues of D-alanyl-D-
alanine, which is an amino acid that makes up 
peptidoglycan. This close relationship allows ß-Lactam 
antibiotics to bind to the active site of penicillin binding 
protiens (PBPs) within bacteria. PBPs facilitate the 
transpeptidation of the cell walls of bacteria. When ß-
Lactam 
antibiotics bind to the active site of PBPs and inhibit 
transpeptidation of peptidoglycan, they prevent cell wall 
synthesis within the bacteria (25). Without cell walls, 
parent cells are not able to undergo mitosis to generate 
a new generation of bacterial cells. Therefore, the 
bacteria are soon eradicated (26).  
 
Where’s the Air 
 
Metronidazole antibiotics only work on anaerobic 
bacteria like H. pylori (27). When a metronadizole 
antibiotic enocunters an anaerobic bacterium, the nitro 
group of the metronidazole is reduced, thus interfering 
with DNA synthesis and making it possible for the 
antibiotic to interact with intracellular macromolecules 
and ultimately kill the bacterium (28). 
 
 
 
Just Say No to Drugs 
 
The reason that there are so many choices in antibiotic 
combinations when considering treatment of H. pylori is 
antibiotic resistance. A patient’s level of resistance to 
an antibiotic can cause a drug regimen to fail in 
erradicating infection. Ecclissato et. al. (2002) studied 
the effects of antibiotic resistance in two common 
regimens used to treat infection by H. pylori. In both a 
three drug regimen and a two drug regimen, it was 
shown that when a patient was resistant to just one 
antibiotic, the overall eradication rate of the regimen 
was decreased by half (28). This has serious 
implications for the treatment of patients for H. pylori 
infection. 
Currently, doctors do not test patients for 
antibacterial resistance before they are prescribed a 
regimen to treat H. pylori infection (28). If these patients 
are resistant to the bacteria, the regimen is likely to fail. 
In countries such as the United States, where drugs are 
readily available ,regimen failure is not as serious as in 
countries where drugs are not easily obtained (28). 
 Bacteria form resistance to antibiotics in ways 
unique to each antibiotic. H. pylori resistance to ß-
Lactam antibiotics is due to alteration in the Penicillin 
Binding Protein (PBP) (26).  Studies have shown that 
the replacement of the the wild-type HP0597 (PBP1A) 
gene by the Hardenberg PBP1A resulted in a huge 
increase in the minumum inhibitory concentration (MIC) 
of amoxicillin (a ß-Lactam antibiotic) (26).  Antibacterial 
resistance is usually due to the bacteria evolving ways 
to produce ß-Lactamase even in the presence of anti β-
lactam antibiotics. Structural alterations in a PBP or 
changes in other proteins that are involved in cell wall 
synthesis are also involved in antibacterial resistance. 
Macrolide antibiotics face two main modes of 
resistance. There is target site modification, during 
which the bacterium makes an enzyme that methylates 
the rRNA, thus inhibiting the binding of erythromycin (or 
other macrolides) (24). The second mode of resistance 
is alteration in transport of the antibiotic. This mode of 
resistance involves two macrolide efflux pumps: A and 
E. The pumps pump macrolides out of the cell; 
however, this mode of resistance only works on 
fourteen or fifteen membered macrolides (24). 
Metronidazole resistance has been accredited to 
mutations in the rdxA gene that make the gene 
inoperative (29).  This gene coded for an oxygen-
insensitive NADPH nitroreductase (29).  Without the 
expression of this gene, the Metronidazole cannot 
energize its anabolic functions. 
 
Glimpses of Future Glory 
 
Hit Them Where it Hurts 
Currently, Genome-based drugs and vaccines are 
being worked on. Genome-based drugs are drugs that 
attack a specific target, which is essential to cell 
function (21). Researchers are trying to find proteins 
involved in cell envelope synthesis and integrity, cell 
division, protein synthesis, nucleic acid biosynthesis, 
gene expression and regulation, cell metabolism and 
other protein essential to H. pylori function that may be 
easily and safely targeted (21). 
 
Just Give it a Shot 
An important topic of research that many scientists are  
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very interested in is the possibility of a vaccination for  
H. pylori infection. It is believed that a vaccination is 
possible due to the immune response generated by the 
host at the onset of H. pylori infection (29).  It has been 
found that H. pylori actually benefit from this response 
when first colonizing a new host. The antigens formed 
in this process may be used to treat established 
infections (30).  
Most research concerning vaccines has been 
carried out in animal models with promising results. It 
was found by Ghiara et. al. (1997) that mice that had 
chronic H. pylori infection were able to receive 
therapeutic vaccinations of recombinant VacA and 
CagA together with a genetically detoxified mutant of 
the heat-liable enterotoxin LTK63, intragastrically, to 
eradicate H. pylori infection (31). Furthermore, the 
vaccination protected the mice from re-infection for 12 
weeks after eradication (31). 
Using animal models, scientists are currently 
testing different possible vaccines for efficacy and 
safety, as well as considering the best mode of delivery 
(32). A big challenge for scientists to overcome in 
eradicating H .pylori is antibiotic resistance.  
 
Gutsy Alternative Treatments: 
In order to lessen the possibility of antibacterial 
resistance and subsequent ineffectiveness of drugs in 
treating H. pylori, alternative treatments should be 
studied. Some of the alternative methods to antibiotics 
include: Vitamin C supplements, Lactobacilli,  
Mastic gum, and garlic, among others (33). Mastic gum 
is a resinous substance obtained from the stem and 
leaves of the mastic tree (Pistacia lentiscus). The direct 
mechanism of action of mastic gum in healing ulcers 
and eradicating H. pylori should be studied to determine 
its therapeutic properties. Lactobacilli have been shown 
to reduce the incidence of antibiotic-induced 
gastrointestinal side effects such as diarrhea, bloating, 
and taste disturbance.  In addition, clinical evidence 
suggests that Lactobacilli such as L. salivarius enhance 
the effects of antibiotic treatment; however, research 
needs to be conducted to confirm these findings (33).  
 
H. pylori May Be Good 
Some scientists worry that eradication of H. pylori may 
be more harmful than its presence.  Scientists like 
Martin Blaser of Vanderbilt University in Nashville 
suggest that the bacterium's presumed long 
acquaintance with mankind may offer benefits (34). It is 
possible that the benefits of having H. pylori infection 
may balance the costs, or else we would have evolved 
a better immune response. H. pylori have been around 
for at least 100,000 years. This preliminary evidence 
suggests that people who are not infected with H. pylori 
are more likely to develop reflux—a painful disease in 
which acid from the stomach backs through a leaky 
valve and inflames the esophagus. In addition, it is 
possible that the bacterium may also reduce the risk of 
the cancer of the esophagus. While gastroesophageal 
reflux disease is now a growing problem in some  
developed countries, Graham notes that excess acid 
secretion can be easily managed by current 
medications.  The immune response stimulated by H. 
pylori could help the human immune system fight other, 
more harmful, invaders. Putsep et al.  reported that H. 
pylori makes a compound that kills other bacteria. With 
these intriguing findings, Putsep et al. suggest that 
physicians should wait for more studies on possible 
benefits of H. pylori before aggressively pursuing any 
program to eradicate the bacterium (34).  
Conclusion  
 
Since its discovery in 1983, research has shown 
Helicobacter pylori to be the cause of peptic ulcers and 
a contributor to gastric cancer. Further studies on the 
bacterium have given scientists insight into how the 
bacterium functions in the human body and how it may 
be eradicated. Advances in the knowledge of H. pylori 
will help scientists and physicians effectively treat 
gastric and duodenal ulcers as well as gastric cancer. 
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